Moderna's Run-up Looks Like Overreaction from Wall Street
Dow Jones
Aug 20
0824 ET - Moderna shares surging 176% on Wednesday may have been an overreaction from Wall Street to the strong results from Moderna and Merck's mRNA-based vaccine for melanoma patients, UBS analysts say. Moderna's valuation jumped to $70 billion; ascribing a modest valuation to the company's Covid-19 revenue, that would imply a $60 billion valuation to the vaccine alone, which would have to translate to $20 billion in annual sales, the analysts say. That could be unrealistically high, they say. The analysts maintain a $150 price target for Moderna after it closed at $174 on Wednesday. Shares slide 10% to $156.30 premarket.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.